A newer generation of ALK-TKIs, such as ceritinib and alectinib, have demonstrated efficacy in the treatment of crizotinib-resistant ALK-positive NSCLC [112,121,126,131,132,133,134]. This evidence concerns the gene ALK and non-small cell lung carcinoma.